Search clinical trials for: 2nd line therapy

Total 59064 results

Shi Yuankai

Recruiting

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Head and Neck Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colorectal Cancer

China
Sabine Mueller, MD, PhD
National Cancer Institute (NCI); Dana-Farber Cancer Institute; Mithil Prasad... and other collaborators

Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PNOC023)

Glioblastoma | Recurrent Ependymoma | CNS Tumor | Diffuse Midline Glioma (DMG) | Recurrent Malignant Central Nervous System Neoplasm | Spinal Cord Glioma | Central Nervous System Tumor | World Health Organization (WHO) Grade III Glioma

United States, Switzerland
Ruijin Hospital

Recruiting

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Advanced Cervical Cancer

China
LLS PedAL Initiative, LLC
National Cancer Institute (NCI); Children's Oncology Group

Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic Therapy

United States, Canada, Australia, Puerto Rico, New Zealand
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
The Affiliated Hospital of Qingdao University

Recruiting

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Gastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line Therapy

China
National Taiwan University Hospital

Recruiting

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

H. Pylori Infection

Taiwan
Second Affiliated Hospital, School of Medicine,...
Carbiogene Therapeutics Co. Ltd.

Recruiting

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Bristol-Myers Squibb

Recruiting

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

Netherlands, Belgium, United States, Australia, Greece, Italy, Canada, Japan, Poland, Romania, Spain
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Advanced Lung Carcinoma
Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Lung Cancer, Nonsmall Cell

United States
Technical University of Munich
Eli Lilly and Company

Recruiting

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients (Abemacare)

Breast Cancer/ Metastatic Breast Cancer

Germany
Brain Neurotherapy Bio, Inc.

Recruiting

GDNF Gene Therapy for Multiple System Atrophy

Multiple System Atrophy

United States
University of Aarhus
Aarhus University Hospital; Westmead and Blacktown Hospital, Sydney West Radiation...

Recruiting

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer (ASPECT)

Lung Cancer | Pulmonary Disease | Radiation Pneumonitis | Lung Function Decreased | Radiation-Induced Disorder

Australia, Denmark
RenJi Hospital

Recruiting

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV

China
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
China-Japan Friendship Hospital

Not yet recruiting

Effects of COPD Standardized Management on COPD Exacerbation

Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Philogen S.p.A.

Recruiting

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC)

Soft Tissue Sarcoma

Spain, Germany, France, Italy, Poland
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Guangdong Provincial People's Hospital
Guangzhou First People's Hospital; Foshan First People's Hospital; Huizhou Municipal... and other collaborators

Recruiting

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years (R2DLBCL80)

Diffuse Large B Cell Lymphoma | Age Over 80 Years

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Stony Brook University

Recruiting

Harnessing Network Science to Personalize Scalable Interventions for Adolescent Depression (TRACK to TREAT Phase 2)

Depression

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
The Second Hospital of Shandong University

Not yet recruiting

NK Cell Therapy Recurrent/Refractory Elderly AML

AML | Elderly | Recurrent | Refractory

China
University of Wisconsin, Madison
Doris Duke Charitable Foundation

Recruiting

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Metastatic Colorectal Cancer

United States
Criterium, Inc.

Recruiting

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE)

Breast Cancer

United States
St. Jude Children's Research Hospital
Incyte Corporation; North American Consortium for Histiocytosis; Cures Within...

Recruiting

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytosis

United States
Beijing Chest Hospital

Recruiting

Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

Tuberculosis

China
October 6 University
Beni-Suef University

Recruiting

Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

Pneumonia

Egypt
National Cancer Institute (NCI)

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Puerto Rico, Israel
Children's Hospital of Fudan University

Recruiting

Airway Microbiota Based Treatment of Asthma in Preschool Children (AMBT)

Asthma in Children

China
Peking University

Recruiting

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Hepatocellular Carcinoma

China
wang, jianxiang

Not yet recruiting

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Acute Leukemia of Ambiguous Lineage

China
St. Antonius Hospital
Daiichi Sankyo, Inc.

Recruiting

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? (WOEST-3)

Myocardial Infarction | Coronary Artery Disease | Stroke | Embolism | Atrial Fibrillation | Bleeding | Acute Coronary Syndrome | Atrial Flutter | NSTEMI - Non-ST Segment Elevation MI | Stent Thrombosis | STEMI - ST Elevation Myocardial Infarction

Belgium, Netherlands
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
Ohio State University Comprehensive Cancer Center

Recruiting

Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise (VENTED)

COVID-19

United States
Institut Claudius Regaud

Recruiting

Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy (BLAD-RAD01)

Urothelial Bladder Cancer

France
Anke Haberkamp

Recruiting

Gamification in the Treatment of Spider Phobia

Spider Phobia

Germany
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
National Pediatric Cancer Foundation

Recruiting

Evolutionary Therapy for Rhabdomyosarcoma

Rhabdomyosarcoma

United States
Technische Universität Dresden
Pfizer; Novartis Pharmaceuticals

Recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC)

Acute Myeloid Leukemia

Germany
Grupo Español de Linfomas y Transplante Autólogo...

Recruiting

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (BRESELIBET)

Hodgkin Lymphoma, Adult

Spain

Search clinical trials for: 2nd line therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations